The rising burden of female cancer in Ethiopia (2000–2021) and projections to 2040: Insights from the global burden of disease study
PLOS One · 2025
DOI: 10.1371/journal.pone.0333787 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Molalign Aligaz Adisu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and child health Nursing, College of Health science, Woldia University, Woldia, Ethiopia. Hauptthemen laut MEDLINE: Global Burden of Disease, Uterine Cervical Neoplasms, Breast Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Female cancers—breast, cervical, ovarian, and uterine—pose significant public health and socio-economic challenges, particularly in low- and middle-income countries like Ethiopia. However, detailed and geographically disaggregated data are limited, hindering effective policymaking. To address this gap, our study utilizes the Global Burden of Disease (GBD) methodology to analyze 21 years (2000–2021) of national and sub-national trends and risk factors for these cancers in Ethiopia, with projections to 2040, to support targeted cancer control and health system strengthening.
Methods
Using the 2021GBD data, we analyzed the national and sub-national prevalence, incidence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) for female specific cancer in Ethiopia. An Autoregressive Integrated Moving Average (ARIMA) model was employed for projecting epidemiological trajectories through 2040. All statistical analyses and data visualization were performed using Python.
Results
In 2021, the Ethiopian incidence of female breast, cervical, ovarian, and uterine cancer was 7,308 (95% uncertainty interval (UI): 5,794–9,199), 7,884 (95% UI: 5,759–11,765), 2,054 (95% UI: 1,034–2,929), and 669 (95% UI: 422–1,126), respectively. Cervical cancer accounts for the highest number of DALYs, 162,776 (95% UI: 119,900–239,116), followed by breast, ovarian, and uterine cancer at 155,931 (95% UI: 123,015–196,249), 40,430 (95% UI: 19,885–57,414), and 8,882 (95% UI: 5,579–15,240), respectively. Projections to 2040 indicate a continued rise in incidence for all female cancers.
Conclusions
Breast and ovarian cancers are emerging public health crises in Ethiopia, with significant increases in prevalence, incidence, and DALYs. While the cervical cancer burden is declining, rising YLDs indicate a growing need for long-term care. The projected rise in female cancer incidence calls for urgent, targeted interventions focused on early diagnosis, age-appropriate screening, and improved cancer care services to reduce the adverse impact on Ethiopian women's health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pediatrics and child health Nursing, College of Health science, Woldia University, Woldia, Ethiopia.
- Department of Nursing, College of Health science, Woldia University, Woldia, Ethiopia.
ORCID-Profile: Molalign Aligaz Adisu
Zitieren
APA
Adisu, M. A., Habtie, T. E., Kitaw, T. A., Gessesse, A. D., Woreta, B. M., Derso, Y. A., & Zemariam, A. B. (2025). The rising burden of female cancer in Ethiopia (2000–2021) and projections to 2040: Insights from the global burden of disease study. PLOS One. https://doi.org/10.1371/journal.pone.0333787
Vancouver
Adisu MA, Habtie TE, Kitaw TA, Gessesse AD, Woreta BM, Derso YA, et al. The rising burden of female cancer in Ethiopia (2000–2021) and projections to 2040: Insights from the global burden of disease study. PLOS One. 2025. doi:10.1371/journal.pone.0333787
BibTeX
@article{Adisu2025,
author = {Adisu, Molalign Aligaz and Habtie, Tesfaye Engdaw and Kitaw, Tegene Atamenta and Gessesse, Abraham Dessie and Woreta, Bogale Molla and Derso, Yabibal Asfaw and Zemariam, Alemu Birara},
title = {The rising burden of female cancer in Ethiopia (2000–2021) and projections to 2040: Insights from the global burden of disease study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333787}
}
EUVIMED